Adriana Rossi, M.D.

Hematology
Adriana Rossi

 

Adriana Rossi, M.D., is an Assistant Professor of Medicine at Weill Cornell Medical College and Assistant Attending Physician at the NewYork-Presbyterian Hospital. 

 After graduating from the University of Michigan with a B.S. in cellular and molecular biology, Dr. Rossi obtained a Master of Health Science from Johns Hopkins University in 2002.  Starting out as a bench researcher, she worked at several top rated laboratories gaining valuable research skills.  Following her experience in the planning and implementing of laboratory based research projects, she obtained her M.D. from George Washington University in 2007.  She completed her residency in Internal Medicine at Thomas Jefferson University Hospital in 2010, followed by a three-year fellowship in Hematology/Oncology at Weill Cornell Medical College/the New York-Presbyterian Hospital.  Upon completion of her fellowship, she was recruited to a faculty position in support of the Division’s Myeloma Program.

 Dr. Rossi works with Drs. Ruben Niesvizky, Tomer Mark, Roger Pearse, as well as other faculty members in Hematological Malignancies to develop sponsored clinical and translational research activities and to foster growth and development of the Myeloma Program.  She is developing research projects pertaining to measurement of minimal residual disease, and focuses on novel approaches for relapsed and refractory myeloma including new drug development.   She also works in support of the myeloma autologous stem cell transplant program under the guidance of Drs. Tomer Mark and Koen van Besien. 

 

Insurances

Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please feel free to contact this physician or this physician's practice as they may have individual contracts not included on this site.

  • AETNA [HMO]
  • AETNA [PPO]
  • AETNA [Medicare]
  • Aetna - Weill Cornell [POS]
  • Affinity Essential
  • Affinity Health Plan
  • Blue Priority Network
  • CIGNA
  • Emblem Select Care
  • Empire Blue Cross/Blue Shield [Pathway X]
  • Empire Blue Cross/Blue Shield [Pathway X Enhanced]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [EPO]
  • Empire Blue Cross/Blue Shield [HMO]
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Fidelis Care
  • GHI [CBP]
  • Health First
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Insurance Plan of NY (HIP)
  • Health Insurance Plan of NY (HIP) [Medicaid]
  • Health Plus - Amerigroup [CHP]
  • Health Plus - Amerigroup
  • Health Republic
  • Oscar
  • Oxford Health Plans [Medicare Advantage]
  • Oxford Health Plans [Freedom]
  • Oxford Health Plans [Liberty]
  • POMCO
  • Rockefeller University - CoreSource
  • UHC Compass
  • United Empire
  • United Health Care [Medicare]
  • United Health Care
  • United Health Care [Community Plan]
  • VNSNY CHOICE Medicare [Medicare]
  • VNSNY CHOICE Medicare [HMO]

Publications

1.  Roboz GJ, Bennett JM, Coleman M, Ritchie EK, Furman RR, Rossi A, Jhaveri K, Feldman EJ, Leonard JP. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma. Leuk Res. 2007; 31(8):1141-4. 

2.  Jain N, Rossi A, Garcia-Manero G. Epigenetic therapy of leukemia: An update.  Int J Biochem Cell Biol. 2009; 41(1):72-80. 

3.  Sampat K, Rossi A, Garcia-Gutierrez V, Cortes J, Pierce S, Kantarjian H, Garcia-Manero G.Characteristics of pericardial effusions in patients with leukemia. Cancer. 2010; 116(10): 2366-71.

4.  Rossi A, Mark T, Jayabalan D, Christos P, Zafar F, Pekle K, Pearse R, Chen-Kiang S, Coleman M, and Niesvizky R. BiRd (clarithromycin, lenalidomide, dexamethasone): An update on long term lenalidomide therapy in previously untreated patients with multiple myeloma. Blood. Epub 2013.

Honors and Awards

 K30 – Masters in Clinical Investigation   06/2011

 KL2 – Post-Doctoral Scholars Award    06/2012